Ignite Creation Date:
2024-05-06 @ 6:21 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05638594
Status:
RECRUITING
Last Update Posted:
2023-03-20
First Post:
2022-11-24
Brief Title:
Pyrotinib Combined With Trastuzumab Dalpiciclib Letrozole Versus TCbHP Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin as Neoadjuvant Treatment in HR HER2 Breast Cancer
Sponsor:
Shengjing Hospital
Organization:
Shengjing Hospital
Organization Data
Organization:
Shengjing Hospital
Class:
OTHER
Study ID:
MUKDEN-09
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shengjing Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Caigang Liu
Responsible Party Title:
Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shengjing Hospital
Old Name:
None
Old Organization:
None